MX2019010997A - Entrega oral de sustancias fisiologicamente activas. - Google Patents

Entrega oral de sustancias fisiologicamente activas.

Info

Publication number
MX2019010997A
MX2019010997A MX2019010997A MX2019010997A MX2019010997A MX 2019010997 A MX2019010997 A MX 2019010997A MX 2019010997 A MX2019010997 A MX 2019010997A MX 2019010997 A MX2019010997 A MX 2019010997A MX 2019010997 A MX2019010997 A MX 2019010997A
Authority
MX
Mexico
Prior art keywords
physiologically active
active substance
stomach
carrier
active substances
Prior art date
Application number
MX2019010997A
Other languages
English (en)
Inventor
Wang Xueyan
Mantripragada Sankaram
Amer Luke
M Campbell Kathleen
Original Assignee
Rezolute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rezolute Inc filed Critical Rezolute Inc
Publication of MX2019010997A publication Critical patent/MX2019010997A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las realizaciones pueden incluir una composición para la administración oral de medicamentos. La composición puede incluir una sustancia fisiológicamente activa, un compuesto portador, un compuesto mucoadhesivo y un potenciador de la permeación. La sustancia fisiológicamente activa puede ser transportada a través del estómago. La sustancia fisiológicamente activa puede ser estable y no degradarse en el ambiente hostil del jugo gástrico. Para ayudar a proteger la sustancia fisiológicamente activa, esta se mezcla con el vehículo. El vehículo puede ser un líquido insoluble en el jugo gástrico del estómago La sustancia fisiológicamente activa puede ser soluble en el portador. Se puede usar el compuesto mucoadhesivo para promover la adsorción de la sustancia fisiológicamente activa en el revestimiento del estómago. El potenciador de permeación puede facilitar el transporte de la sustancia fisiológicamente activa a través de la pared del estómago.
MX2019010997A 2017-03-23 2018-03-16 Entrega oral de sustancias fisiologicamente activas. MX2019010997A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475624P 2017-03-23 2017-03-23
US15/922,651 US20180271792A1 (en) 2017-03-23 2018-03-15 Oral delivery of physiologically active substances
PCT/US2018/022928 WO2018175250A1 (en) 2017-03-23 2018-03-16 Oral delivery of physiologically active substances

Publications (1)

Publication Number Publication Date
MX2019010997A true MX2019010997A (es) 2019-10-17

Family

ID=63581994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010997A MX2019010997A (es) 2017-03-23 2018-03-16 Entrega oral de sustancias fisiologicamente activas.

Country Status (11)

Country Link
US (1) US20180271792A1 (es)
EP (1) EP3600380A1 (es)
JP (1) JP2020511478A (es)
KR (1) KR20190126433A (es)
CN (1) CN110662550A (es)
AU (1) AU2018237678A1 (es)
BR (1) BR112019019596A2 (es)
CA (1) CA3055421A1 (es)
MX (1) MX2019010997A (es)
RU (1) RU2019133551A (es)
WO (1) WO2018175250A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CN112057619A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
US20220184166A1 (en) * 2020-12-10 2022-06-16 Theo Rallis Discrete phase particles including compounds from olea europaea
CN113209280B (zh) * 2021-03-07 2022-03-25 合肥天汇孵化科技有限公司 甲状旁腺激素组合物及其用途
CN113053453B (zh) * 2021-03-15 2022-01-04 中国农业科学院农业质量标准与检测技术研究所 应用转录组学筛选全氟辛烷磺酸毒性枢纽基因和关键信号通路的方法
US20230053812A1 (en) * 2021-07-27 2023-02-23 Aurobindo Pharma Ltd Stable peptide formulations for oral use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6001821A (en) * 1995-12-19 1999-12-14 Pitha; Josef Dioxane-substituted cyclodextrin macromolecules and inclusion complexes
US5935941A (en) * 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5830969A (en) * 1997-05-28 1998-11-03 Dow Corning Corporation Silyl ester initiators for ring opening polymerization of cyclosiloxanes
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
JP2008533101A (ja) * 2005-03-17 2008-08-21 ノボ ノルディスク アクティーゼルスカブ 肥満の治療において使用するための化合物
UA114700C2 (uk) * 2007-10-16 2017-07-25 Біокон Лімітед Тверда фармацевтична форма для перорального застосування та процес її виготовлення
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates

Also Published As

Publication number Publication date
RU2019133551A (ru) 2021-04-23
US20180271792A1 (en) 2018-09-27
AU2018237678A1 (en) 2019-10-03
BR112019019596A2 (pt) 2020-04-22
WO2018175250A1 (en) 2018-09-27
EP3600380A1 (en) 2020-02-05
CN110662550A (zh) 2020-01-07
KR20190126433A (ko) 2019-11-11
JP2020511478A (ja) 2020-04-16
CA3055421A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
MX2019010997A (es) Entrega oral de sustancias fisiologicamente activas.
EP4233978A3 (en) Oral delivery of active drug substances
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
MX2010008234A (es) Nueva dosificacion y formulacion.
MY177027A (en) Novel dosage and formulation
CY1124104T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
JP2016196511A5 (es)
DOP2010000318A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
DE602007010254D1 (de) Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
MX350871B (es) Vehiculo masticable para absorcion bucal.
UA92011C2 (ru) Облатка, содержащая стероидные гормоны
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
MX2021003271A (es) Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2).
PH12014502619A1 (en) Novel dosage and formulation
MX2018010755A (es) Pelicula transmucosal de montelukast.
MX2019015733A (es) Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.
EA201401200A1 (ru) Новая композиция альфентанила для лечения острой боли
WO2016014680A3 (en) Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men
PE20220932A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso
MY194945A (en) Oral administration of unstable or poorly-absorbed drugs
WO2016028903A8 (en) Oral transmucosal pharmaceutical compositions including testosterone and a c-serm
PL417092A1 (pl) Innowacyjne połączenie symetykonu, związku zobojętniającego w postaci węglanu oraz technologii tabletek flotacyjnych do stosowania w nadkwaśności żołądka
WO2014191806A3 (en) Effervescent formulations that deliver particles which float in the stomach
Yu et al. Bouveret's syndrome: a rare cause of gastric outlet obstruction